A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 05 Jun 2019 This trial has been completed in Italy, according to European Clinical Trials Database.
- 15 Nov 2017 Status changed from active, no longer recruiting to completed.
- 12 Oct 2017 This trial is completed in Czech Republic.